Zevtera
Generic name: ceftobiprole medocaril
Treatment for: Bacteremia, Skin and Structure Infection, Pneumonia
FDA Issues Complete Response Letter for Ceftobiprole
FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
RARITAN, N.J., November 26, 2008 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.
The FDA has indicated that they cannot approve the NDA for ceftobiprole at this time. They have asked J&JPRD to conduct additional audit work of clinical investigator sites and to address specific questions related to site monitoring.
J&JPRD and its co-development partner, Swiss-based Basilea Pharmaceutica Ltd., are reviewing the Complete Response letter and will continue to work with the FDA to resolve questions that are outlined in the Complete Response letter.
The NDA for ceftobiprole was submitted to the FDA in May 2007, and, in March 2008, J&JPRD received an Approvable Letter regarding the ceftobiprole filing. J&JPRD responded to the FDA's Approvable Letter in August 2008.
Ceftobiprole was approved earlier this year in Canada, and most recently it was approved in Switzerland. Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval of ceftobiprole in the European Union for the treatment of complicated skin and soft tissue infections.
Ceftobiprole is a novel, broad-spectrum, anti-MRSA cephalosporin with activity against methicillin-resistant (MRSA), penicillin-resistant and many clinically important Gram-negative bacteria, including .
MRSA is a type of bacteria that is resistant to certain antibiotics. These antibiotics include methicillin and other more common antibiotics such as oxacillin, penicillin and amoxicillin. Staphylococcal (frequently called "Staph") infections, including MRSA, previously occurred most frequently among persons in hospitals and healthcare facilities who have weakened immune systems. Increasingly, cases are being reported in outpatient and community settings. These cases are referred to as community-associated MRSA (CA-MRSA) and are a growing healthcare concern.
J&JPRD is part of Johnson & Johnson, the world's most broadly based producer of healthcare products. J&JPRD is headquartered in Raritan, NJ, and has facilities throughout Asia, Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.
[This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.]
CONTACT: Media: Greg Panico, +1-908-927-3715 (office), or +1-908-240-2011(cell); Investor Relations: Stan Panasewicz, +1-732-524-2524 or Tina Pinto,+1-732-524-2034
Web site: http://www.jnj.com/
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: November 2008
Related articles
- FDA Approves Zevtera (ceftobiprole medocaril sodium) for Bacteremia, Skin and Skin Structure Infections, and Pneumonia - April 4, 2024
- Basilea Announces FDA Acceptance of New Drug Application for Antibiotic Ceftobiprole - October 2, 2023
- Basilea Announces Submission of a New Drug Application to the US Food and Drug Administration for its Antibiotic Ceftobiprole - August 4, 2023
- FDA Issues Complete Response Letter for Ceftobiprole - December 30, 2009
- FDA accepts for review the Complete Response submission to ceftobiprole NDA - September 3, 2009
- FDA accepts for review the Complete Response to ceftobiprole NDA Approvable Letter - September 15, 2008
- FDA Issues Approvable Letter for Ceftobiprole for Treatment ofComplicated Skin Infections - March 18, 2008
- FDA Published Today That It Will Not Hold an Advisory CommitteeMeeting on Ceftobiprole in the Treatment of Complicated Skin andSkin Structure Infections - February 13, 2008
- Basilea Announces Review of Ceftobiprole NDA at FDA Anti-Infective Drugs Advisory Committee Meeting - January 10, 2008
- U.S. FDA and European EMEA Accept Registration Applications for Ceftobiprole, Novel Anti-MRSA Broad-Spectrum Cephalosporin - July 18, 2007
- New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole - May 18, 2007
Zevtera (ceftobiprole medocaril) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
